Compare American Superconductor Corporation (AMSC) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Charles River Laboratories Intl. Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Charles River Laboratories Intl. Inc trades at $233.41 (market cap $11.24B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.5× American Superconductor Corporation's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | CRL | |
|---|---|---|
Market Cap | $1.74B | $11.24B |
Sector | Technology | Health |
52-Week High | $66.68 | $233.60 |
52-Week Low | $25.95 | $145.57 |
Enterprise Value | $1.61B | $14.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
Charles River Laboratories (CRL) trades at $233.41, down slightly by 0.08% today, with a bullish technical signal supported by moving averages. The company shows strong operational cash flow of $737.65M for 2025 but faces profitability challenges with negative net income margin of -4.59% and ROE of -6.02%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly positive with 72% buy ratings.
CRL presents a mixed investment case: strong cash generation and strategic collaborations like the Lilly TuneLab partnership provide growth catalysts, but negative profitability metrics and high valuation ratios (P/E 684.85) pose risks. The stock's outlook depends on margin improvement and successful execution of recent business initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
